Research brief · 2026-09-09
What Does Ipamorelin Actually Do? What the Research Shows
Ipamorelin is a synthetic pentapeptide, a chain of five amino acids designed in a laboratory rather than copied from a human hormone. It was engineered by Novo Nordisk researchers to act on the growth hormone secretagogue receptor, the same docking site used by ghrelin, the body's hunger hormone. Triggering that receptor causes the pituitary gland to release a pulse of growth hormone. Ipamorelin is not approved as a medicine anywhere, and the evidence behind it is mostly animal studies.
The animal pharmacology is real. In the original 1998 study by Raun and colleagues in the European Journal of Endocrinology, ipamorelin reliably triggered growth hormone release in rats and pigs. Unlike some related compounds, it did not meaningfully raise cortisol or ACTH, the stress hormones, which is why it is often described as selective.
The human record is stranger. Two trials are registered on ClinicalTrials.gov, both sponsored by Helsinn Therapeutics and both completed. A Phase 2 dose-finding trial enrolled 320 patients recovering from bowel resection surgery and finished in 2014. An earlier Phase 2 trial enrolled 117 patients with post-operative ileus and finished in 2009. Both tested whether ipamorelin could speed the return of normal bowel function after surgery.
Neither trial has ever posted results on the registry, and no published journal article describing what either found could be located. That is the central fact about ipamorelin: a pharmaceutical company ran a controlled hospital trial in 320 people, and the outcome was never made public. Notably, neither trial studied muscle growth, fat loss, sleep or anti-aging, the uses it is most commonly marketed for today.
The limit of the evidence is that there is almost none in humans. Whether the low-cortisol effect seen in animals holds with repeated use in people, whether it does anything for muscle or aging in healthy adults, and what long-term hormonal effects it might have are all untested. Ipamorelin is not approved for human use.
Sources
- Raun K et al., Ipamorelin, the first selective growth hormone secretagogue (rat and pig pharmacology)
- European Journal of Endocrinology 1998
- ClinicalTrials.gov NCT01280344, ipamorelin for recovery of gastrointestinal function after bowel resection, Helsinn Therapeutics, n=320, completed 2014, no results posted
- ClinicalTrials.gov 2014
- ClinicalTrials.gov NCT00672074, ipamorelin for post-operative ileus, Helsinn Therapeutics, n=117, completed 2009, no results posted
- ClinicalTrials.gov 2009
Peptide Proof reports what studies found. We do not give medical advice, dosing guidance, or treatment recommendations.